- Patent Title: Glucagon-receptor selective polypeptides and methods of use thereof
-
Application No.: US16667502Application Date: 2019-10-29
-
Publication No.: US11214607B2Publication Date: 2022-01-04
- Inventor: William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
- Applicant: Intarcia Therapeutics Inc.
- Applicant Address: US MA Boston
- Assignee: Intarcia Therapeutics Inc.
- Current Assignee: Intarcia Therapeutics Inc.
- Current Assignee Address: US MA Boston
- Agency: Lathrop GPM LLP
- Agent Brian C. Trinque
- Main IPC: C07K14/605
- IPC: C07K14/605 ; C07K14/00 ; A61K38/26 ; A61K9/00 ; A61M5/142 ; A61M31/00 ; A61M5/145

Abstract:
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
Public/Granted literature
- US20200299350A1 GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF Public/Granted day:2020-09-24
Information query